Clinical trial · Interventional
A Study of Haploidentical Bone Marrow Transplant for Patients With Hematologic Malignancies
A Phase 2 Study of Nonmyeloablative Conditioning With Transplantation of Partially Human Leukocyte Antigen (HLA)-Mismatched Bone Marrow and Post-transplant Cyclophosphamide for Patients With Hematologic Malignancies
NCT02623439CI-TRIAL-00097068terminatedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Toxicity
Summary
Brief summary (as posted)
The primary objective is to determine overall survival 180 days after transplantation involving HLA-haploidentical stem cell/bone marrow graft, and post-transplant Cy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematologic Malignancies | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- cyclophosphamide post BMT
- description
- Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant
- interventionNames
- Drug: Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant
Primary outcomes (1)
- measure
- Overall Survival
- timeFrame
- Day 180
- description
- 180 days after transplantation
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age: Subjects 18-70 years old. 2. Donor must be 18 years of age. 3. HLA typing will be performed at high resolution. A minimum match of 5 out of 10 is required. 4. Patients must have received multi-agent chemotherapy within 3 months of consent date (measured from the start date of chemotherapy). 5. Acute Leukemias. * Acute Lymphoblastic Leukemia in high risk 1st complete response (CR1) * Acute Myelogenous Leukemia in high risk 1st complete response (CR1) * Acute Leukemias in 2nd or subsequent Complete Response (CR) * Biphenotypic/Undifferentiated Leukemias in 1st or subsequent Complete Response (CR). 6. Burkitt's lymphoma: second or subsequent Complete Response (CR). 7. Lymphoma 8. Patients with adequate physical function 9. Performance status: Karnofsky score 70-100%. Exclusion Criteria:
References
Publications (0)
Data not yet available
No reference posted for this study.